Teknova Announces Proposed Public Offering of Common Stock
Key Highlights
- ➤Teknova (TKNO) commenced an underwritten public offering of common stock.
- ➤Underwriters may purchase up to 15% additional shares through a 30-day option.
- ➤Proceeds may fund general corporate purposes, including potential debt repayment.
- ➤Teknova may use proceeds for complementary acquisitions or technology investments.
- ➤Offering size, terms, and completion remain subject to market conditions.
HOLLISTER, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that it has commenced an underwritten public offering of its common stock. Teknova also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of shares of its common stock offered in the offering. All of the shares of common stock to be sold in the proposed offering are to be sold by Teknova. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering.
TD Cowen and William Blair are acting as joint book-running managers for the proposed offering.
Get started
Create a free account to read the full story.